BSH 2024 - 64th British Society for Haematology Annual Scientific Meeting
Apr 28 - Apr 30, 2024 | LiverpoolUK
LARVOL is not affiliated with 64th British Society for Haematology Annual Scientific Meeting and all trademarks, logos, and brand names are property of their respective owners
Showing 61 abstracts linked to Trials
BSH24-OR19 - ANIMATE: A UK Phase II PET Response-Adapted Trial of Nivolumab in Relapsed Classical Hodgkin Lymphoma
BSH24-OR23 - Epcoritamab Monotherapy Leads to Deep and Durable Responses in R/R FL: Pivotal EPCORE NHL-1 Data
BSH24-OR20 - Fixed-Duration Glofitamab Monotherapy in Relapsed/Refractory Large B-Cell Lymphoma: Phase II Extended Follow-Up and Subgroup Analyses
BSH24-OR31 - Etranacogene Dezaparvovec HOPE-B 3-year results in Adult Patients With Severe or Moderately Severe Haemophilia B
BSH24-OR36 - Paediatric use of rivaroxaban for cerebral venous sinus thrombosis: A multi-centre clinical audit
BSH24-OR08 - Integrated Assessment of Transfusion, Anaemia, and Survival in Myelofibrosis: Insights from SIMPLIFY-1 and SIMPLIFY-2 Trials
BSH24-OR40 - Obecabtagene Autoleucel (Obe-Cel) for Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukaemia: FELIX Phase Ib/II Pooled Analysis
Industry Educational Session - Navigating the changing treatment landscape of relapsed refractory DLBCL - Sponsored by Sobi
BSH24-OR44 - Sonrotoclax (BGB-11417) + Zanubrutinib in Patients With Treatment-Naive CLL/SLL: An Ongoing Phase 1/2 Study
BSH24-OR45 - Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: Elevate-TN 6-year Follow-Up
BSH24-OR46 - NHS-Ready Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients
BSH24-OR25 - Patient-reported outcomes: danicopan add-on therapy to ravulizumab/eculizumab in patients with PNH and clinically significant EVH
BSH24-OR26 - Efficacy and Safety Maintained in Adult PNH Patients Receiving Pegcetacoplan for Up to 3 Years
BSH24-EP166 - Rituximab prior to venetoclax is safe and effective in relapsed/refractory chronic lymphocytic
BSH24-EP12 - Long term outcomes of stem-cell- transplant in older patients with AML treated with venetoclax HMA therapies